1.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-97.

2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202:1028-34.

3. Fuchs FD, Klag MJ, Whelton PK. The classics: a tribute to the fiftieth anniversary of the randomized clinical trial. J Clin Epidem 2000; 53: 335-42.

4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA 1970; 213:1143-52.

5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-38.

6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265:3255-64.

7. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Br Med J 1992: 304:405-12.

8. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-85.

9. Neaton JD, Grimm Jr RH, Prineas RJ, Stamler J, Grandits GA, Elmer P, et al. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA. 1993; 270:713-10.

10. Phillipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorotiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315:154-59.

11. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291:97-104.

12. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852-57.

13. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35:1025-30.

14. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18:1149-54.

15. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277:739-45.

16. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-64.

17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53

18. Svensson P, Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38:e28-e32.

19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.

20. The Seventh Report of the Joint National Committee on prevention, detection and treatment of high blood pressure. JAMA 2003; 289: 2560-72.

21. Hansson L, Lindoholm LH, Niskanen L, Lanke J, Hedneer T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-16.

22. Hansson L, Lindoholm LH, Ekbom T, Dahölof B, Lanke J, Webster PO, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-56.

23. Fuchs FD. What does STOP-2 tell us about management of hypertension? (letter to the editor). Lancet 2000; 355: 651.

24. Strandberg TE, Salomaa UV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Cardiovascular morbidity and multifactorial primary prevention: fifteen-year follow-up of the Helsinki Businessmen Study. Nutr Metab Cardiov Dis 1995; 5:7-15.

25. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunatan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive therapies. JAMA 1995; 274:620-25.

26. Estacio RO, Barriet W, Jeffers MS, Hiatt WB, Biggerstaff SL, Gifford N, Schrier RW. The effect of Nisoldipine as compared with Enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-52.

27. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.

28. Wright JT JR, Bakris G, Greeene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-31.

29. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and b -blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-65.

30. Brown MJ, Palmer CR, Castaigne A, Leew PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study (INSIGHT). Lancet 2000; 356:366-72.

31. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM; INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003;41:431-6.

32. Fuchs FD. May we die twice? Hypertension 2003; 42:e8.

33. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

34. Lindoholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, Faire U, et al for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.

35. Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study (letter to the editor). Lancet 2002; 359: 2203.

36. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.

37. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259:1976-82.

38. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GR, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.

39. Black HR, Elliott WJ, Grandits G et al. Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 2003; 289: 2073-2082.

40. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 2003; 289:2128-31.

41. ALLHAT Officers. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. JAMA 2000; 283:1967-75.

42. Vários autores. Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors. JAMA 2003; 289:2066-70.

43. Jackson T. Wright, Jr; Barry R. Davis; Jeffrey A. Cutler Consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors—Reply. JAMA 2003; 289:2069-70.

44.Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 2003; 362: 1527-35

45. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-44.

46. Fuchs FD. Diuretics: again the first step in the treatment of most patients with hypertension. Curr Control Trials Cardiovasc Med 2001; 2: 244-48.

47. Fuchs FD. Diuretics: drugs of choice for the initial management of patients with hypertension. Expert Rev Cardiovasc Ther 2003 1: 89-95.